[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL1814527T3 - Dwuwarstwowe tabletki zawierające telmisartan i amlodypinę - Google Patents

Dwuwarstwowe tabletki zawierające telmisartan i amlodypinę

Info

Publication number
PL1814527T3
PL1814527T3 PL05810652T PL05810652T PL1814527T3 PL 1814527 T3 PL1814527 T3 PL 1814527T3 PL 05810652 T PL05810652 T PL 05810652T PL 05810652 T PL05810652 T PL 05810652T PL 1814527 T3 PL1814527 T3 PL 1814527T3
Authority
PL
Poland
Prior art keywords
telmisartan
amlodipine
bilayer tablet
bilayer
tablet
Prior art date
Application number
PL05810652T
Other languages
English (en)
Other versions
PL1814527T5 (pl
Inventor
Wolfram Eisenreich
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35757435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1814527(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PL1814527T3 publication Critical patent/PL1814527T3/pl
Publication of PL1814527T5 publication Critical patent/PL1814527T5/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL05810652T 2004-11-05 2005-10-29 Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę PL1814527T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04026234 2004-11-05
EP05810652.7A EP1814527B2 (en) 2004-11-05 2005-10-29 Bilayer tablet comprising telmisartan and amlodipine
PCT/EP2005/011596 WO2006048208A1 (en) 2004-11-05 2005-10-29 Bilayer tablet comprising telmisartan and amlodipine

Publications (2)

Publication Number Publication Date
PL1814527T3 true PL1814527T3 (pl) 2014-05-30
PL1814527T5 PL1814527T5 (pl) 2021-08-02

Family

ID=35757435

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05810652T PL1814527T5 (pl) 2004-11-05 2005-10-29 Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę

Country Status (30)

Country Link
US (1) US20060110450A1 (pl)
EP (1) EP1814527B2 (pl)
JP (1) JP5134963B2 (pl)
KR (1) KR20070085801A (pl)
CN (2) CN103083318A (pl)
AR (1) AR051618A1 (pl)
AU (1) AU2005300787B2 (pl)
BR (1) BRPI0517809B1 (pl)
CA (1) CA2582049C (pl)
CY (1) CY1114957T1 (pl)
DK (1) DK1814527T4 (pl)
EA (1) EA013053B1 (pl)
ES (1) ES2452019T5 (pl)
HR (1) HRP20140212T1 (pl)
IL (1) IL182926A (pl)
ME (1) ME01615B (pl)
MX (1) MX366895B (pl)
MY (1) MY150758A (pl)
NO (1) NO20071514L (pl)
NZ (1) NZ555284A (pl)
PE (2) PE20061046A1 (pl)
PL (1) PL1814527T5 (pl)
PT (1) PT1814527E (pl)
RS (1) RS53141B (pl)
SI (1) SI1814527T1 (pl)
TW (1) TWI355268B (pl)
UA (1) UA89065C2 (pl)
UY (1) UY29188A1 (pl)
WO (1) WO2006048208A1 (pl)
ZA (1) ZA200702119B (pl)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5110697B2 (ja) * 2005-06-27 2012-12-26 第一三共株式会社 固形製剤
CA2613417C (en) * 2005-06-27 2011-11-29 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
JP2009537565A (ja) 2006-05-16 2009-10-29 ノップ ニューロサイエンシーズ、インク. R(+)およびs(−)プラミペキソール組成とそれを利用する方法
EP2465500A1 (en) 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease
AR061627A1 (es) * 2006-06-27 2008-09-10 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
TWI488658B (zh) * 2006-12-26 2015-06-21 Daiichi Sankyo Co Ltd 溶出性之改善方法
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
JP2012500283A (ja) 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク. (r)−プラミペキソールを使用した組成物並びにその方法
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
CZ301299B6 (cs) 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
EP2210595A1 (en) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
UA102721C2 (uk) 2009-01-23 2013-08-12 Ханми Сайенс Ко., Лтд. Тверда фармацевтична композиція, яка містить амлодипін і лозартан, і спосіб її отримання
TW201109040A (en) 2009-05-20 2011-03-16 Boehringer Ingelheim Vetmed Oral suspension comprising telmisartan
CN102438598B (zh) * 2009-05-27 2015-06-10 株式会社茶山医化 含有泡腾层的多层片
RU2012101792A (ru) * 2009-06-19 2013-07-27 Нопп Ньюросайенсиз, Инк. Композиции и способы для лечения бокового амиотрофического склероза
CN106176745A (zh) * 2009-06-30 2016-12-07 赛诺菲 包含厄贝沙坦和氨氯地平的固定剂量的固体药用组合物,它们的制备和它们的治疗应用
CN101947219B (zh) * 2009-12-01 2012-04-18 天津市汉康医药生物技术有限公司 一种复方替米沙坦苯磺酸氨氯地平药物组合物及其制备方法
CN102085201B (zh) * 2009-12-08 2014-05-07 华润双鹤药业股份有限公司 阿替洛尔和氨氯地平的双层片剂
CN101797250A (zh) * 2010-04-22 2010-08-11 重庆市力扬医药开发有限公司 一种稳定的复方制剂
CN102274223B (zh) * 2010-06-12 2012-10-24 重庆市力扬医药开发有限公司 含替米沙坦和氨氯地平的复方制剂
EA025946B1 (ru) * 2010-10-27 2017-02-28 Крка, Товарна Здравил, Д. Д., Ново Место Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин
CN102058591A (zh) * 2010-12-16 2011-05-18 施慧达药业集团(吉林)有限公司 一种左旋氨氯地平和替米沙坦的复方制剂
JP2014515359A (ja) * 2011-05-23 2014-06-30 ジエンス ヘンルイ メデイシンカンパニー リミテッド ベンズイミダゾール誘導体を含む固形医薬組成物
CN103169701B (zh) * 2011-12-22 2015-05-13 天津康鸿医药科技发展有限公司 替米沙坦氨氯地平双层片及其制备方法
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
CN103127108B (zh) * 2012-03-12 2015-01-21 成都自豪药业有限公司 替米沙坦氨氯地平片及其制备方法和用途
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
WO2015006708A1 (en) 2013-07-12 2015-01-15 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
KR20160027078A (ko) * 2013-08-02 2016-03-09 길리애드 사이언시즈, 인코포레이티드 라놀라진 및 드로네다론의 제약 조성물
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
PT3033081T (pt) 2013-08-13 2021-06-01 Knopp Biosciences Llc Composições e métodos para o tratamento da urticária crónica
CN103463082A (zh) * 2013-09-10 2013-12-25 扬子江药业集团四川海蓉药业有限公司 一种替米沙坦氨氯地平双层片及其制备方法
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR20150111686A (ko) * 2014-03-26 2015-10-06 주식회사 종근당 산화안정성이 향상된 텔미사르탄 및 (s)-암로디핀을 포함하는 약제학적 제제
CN104000821B (zh) * 2014-06-02 2020-06-19 浙江华海药业股份有限公司 含有替米沙坦和苯磺酸氨氯地平的口服双层片剂及其制备方法
EP3185856B1 (en) * 2014-08-29 2018-05-23 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
CN104188968B (zh) * 2014-09-23 2017-01-18 广西壮族自治区药用植物园 一种抗高血压的口服片剂及其制备方法
JP5871294B1 (ja) * 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
KR101750689B1 (ko) 2015-09-15 2017-06-26 주식회사 종근당 약제학적 복합제제
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
KR101823071B1 (ko) * 2016-02-15 2018-01-29 한림제약(주) 텔미사르탄-함유 정제의 제조방법
JP6411662B2 (ja) * 2016-05-30 2018-10-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 固定容量配合剤
CN109562074A (zh) * 2016-08-11 2019-04-02 因特欧生物制药有限公司 包含替米沙坦的单层片复合制剂
CN106420739A (zh) * 2016-10-31 2017-02-22 扬子江药业集团四川海蓉药业有限公司 一种替米沙坦氨氯地平双层片及其制备方法
KR101883664B1 (ko) 2016-11-29 2018-07-31 안국약품 주식회사 텔미사르탄과 암로디핀을 포함하는 단층 복합정제 및 이의 제조방법
CN107519144A (zh) * 2017-07-25 2017-12-29 江西中医药大学 一种替米沙坦氨氯地平片的制备方法
KR20190023940A (ko) 2017-08-30 2019-03-08 대원제약주식회사 안정성 및 용출율이 개선된 텔미사르탄, 암로디핀 및 로수바스타틴을 함유하는 복합제제 및 그 제조방법
KR20190023939A (ko) 2017-08-30 2019-03-08 대원제약주식회사 텔미사르탄, 암로디핀 및 로수바스타틴을 함유하는 복합제제 및 그 제조방법
KR102108396B1 (ko) * 2018-04-25 2020-05-07 제일약품주식회사 약학적 제제
TWI745725B (zh) * 2019-07-29 2021-11-11 生達化學製藥股份有限公司 速放醫藥組成物
EP4093381A1 (en) 2020-01-20 2022-11-30 Zaklady Farmaceutyczne Polpharma S.A. Bilayer tablet comprising telmisartan and amlodipine
CN116898816A (zh) * 2023-08-31 2023-10-20 北京百奥药业有限责任公司 一种替米沙坦氨氯地平片及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265847A (en) * 1978-03-30 1981-05-05 Kirby Pharmaceuticals Ltd Tabletting process
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
US6162802A (en) 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
US5496831A (en) * 1994-05-13 1996-03-05 The General Hospital Corporation Inhibition of insulin-induced adiposis
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
DE69926750T2 (de) * 1998-06-17 2006-06-29 Bristol-Myers Squibb Co. Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
HU226948B1 (en) * 1999-04-28 2010-03-29 Takeda Pharmaceutical Use of angiotensin ii antagonist for prevention or therapy of progression of simplex retinopathy or preproliferating retinopathy
US6784207B2 (en) * 2000-08-04 2004-08-31 Roche Vitamins Inc. Phytanic acid derivative compositions
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
US20030078190A1 (en) * 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
AR037565A1 (es) * 2001-11-21 2004-11-17 Synthon Bv Formas de sales de amlodipina y procedimientos para prepararlas.
IL162754A0 (en) * 2002-01-16 2005-11-20 Boehringer Ingelheim Pharma Bilayer pharmaceutical tablet comprising telmisartane and a diuretic and preparation thereof
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
EP1818056A1 (de) * 2003-01-16 2007-08-15 Boehringer Ingelheim International Gmbh Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US9029363B2 (en) * 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
WO2005070463A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use

Also Published As

Publication number Publication date
MX2007005235A (es) 2007-07-09
BRPI0517809A (pt) 2008-10-21
UA89065C2 (ru) 2009-12-25
UY29188A1 (es) 2006-06-30
ES2452019T3 (es) 2014-03-31
SI1814527T1 (sl) 2014-03-31
PE20110216A1 (es) 2011-04-16
AU2005300787B2 (en) 2011-05-26
IL182926A0 (en) 2007-09-20
MX366895B (es) 2019-07-30
TWI355268B (en) 2012-01-01
IL182926A (en) 2015-09-24
WO2006048208A1 (en) 2006-05-11
TW200630094A (en) 2006-09-01
DK1814527T3 (da) 2014-01-27
CY1114957T1 (el) 2016-12-14
ZA200702119B (en) 2008-07-30
NO20071514L (no) 2007-03-22
NZ555284A (en) 2008-10-31
ES2452019T5 (es) 2021-06-28
EP1814527B2 (en) 2020-11-18
JP5134963B2 (ja) 2013-01-30
US20060110450A1 (en) 2006-05-25
PT1814527E (pt) 2014-01-16
AU2005300787A1 (en) 2006-05-11
ME01615B (me) 2014-09-20
JP2008518888A (ja) 2008-06-05
AR051618A1 (es) 2007-01-24
HRP20140212T1 (hr) 2014-04-11
EA200700977A1 (ru) 2007-10-26
BRPI0517809B1 (pt) 2022-05-17
KR20070085801A (ko) 2007-08-27
CA2582049C (en) 2010-08-24
PE20061046A1 (es) 2006-11-01
EP1814527A1 (en) 2007-08-08
CN103083318A (zh) 2013-05-08
CA2582049A1 (en) 2006-05-11
MY150758A (en) 2014-02-28
EA013053B1 (ru) 2010-02-26
PL1814527T5 (pl) 2021-08-02
CN101052381A (zh) 2007-10-10
DK1814527T4 (da) 2020-12-07
RS53141B (en) 2014-06-30
EP1814527B1 (en) 2013-12-18

Similar Documents

Publication Publication Date Title
IL182926A0 (en) Bilayer tablet comprising telmisartan and amlodipine
IL182455A0 (en) Bilayer tablet
IL177536A0 (en) Multilayer tablet
HK1082195A1 (en) Orally-dispersible multilayer tablet
IL217916A0 (en) Pharmaceutical products
IL218117A (en) A tablet containing saxagliptin and several layers of coating
ZA200606812B (en) Corn event mir604
IL176923A0 (en) Structured materials and methods
HK1101911A1 (en) Tetrahydrocarbozoles and derivatives
IL183944A0 (en) Combination therapy comprising telmisartan and hydrochlorothiazide
ZA200703976B (en) Pool Chemical Tablet
IL178888A0 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
GB0424323D0 (en) Tablet
IL181938A0 (en) Lercanidipine capsules
ZA200606826B (en) Compression-coated tablets and manufacture thereof
GB0403733D0 (en) Medicaments
GB2426724B (en) Patterning methods and products
PT1584631E (pt) Macromonómeros de polietilenoglicol copolimerizáveis, sua preparação e aplicação
ZA200405240B (en) Bilayer pharmaceutical tablet comprising telmisartan and diuretic and preparation thereof
GB0411624D0 (en) Products and uses thereof
EP1744745A4 (en) PHARMACEUTICAL NITRONES
GB2438839B (en) Packaging and assemblies
EP1816136A4 (en) GPR7 SELECTIVE LIGAND AND APPLICATION THEREOF
ZAA200500028S (en) Tablet
ZAA200500705S (en) Tablet